argenx SE
ARGXDrugs in Pipeline
13
Phase 3 Programs
9
Upcoming Catalysts
8
Next Catalyst
May 1, 2026
10dMarket Overview
Stock performance and key metrics
11 upcoming, 0 past
Other
Argenx announced that COO Karen Massey will become CEO in May 2026, succeeding Tim Van Hauwermeiren. The transition reflects the company's expansion in the rare disease market.
10 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Efgartigimod IV
Generalized Myasthenia Gravis
ARGX-113
Pemphigus Vulgaris
Efgartigimod PH20 SC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
EFG PH20 SC
Active Idiopathic Inflammatory Myopathy
IVIG (Intravenous Immunoglobulin)
Multifocal Motor Neuropathy (MMN)
Efgartigimod
Postural Orthostatic Tachycardia Syndrome
empasiprubart
Chronic Inflammatory Demyelinating Polyneuropathy
Prednisone
Bullous Pemphigoid
Empasiprubart IV
Chronic Inflammatory Demyelinating Polyneuropathy
ARGX-119
Amyotrophic Lateral Sclerosis
ARGX-117
Multifocal Motor Neuropathy
efgartigimod PH20 SC in stage B
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ARGX-119 IV
Spinal Muscular Atrophy (SMA)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efgartigimod IV | Phase 3 | Generalized Myasthenia Gravis | - | - |
ARGX-113 | Phase 3 | Pemphigus Vulgaris | - | - |
Efgartigimod PH20 SC | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
EFG PH20 SC | Phase 3 | Active Idiopathic Inflammatory Myopathy | - | - |
IVIG (Intravenous Immunoglobulin) | Phase 3 | Multifocal Motor Neuropathy (MMN) | - | - |
Efgartigimod | Phase 3 | Postural Orthostatic Tachycardia Syndrome | - | - |
empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Prednisone | Phase 3 | Bullous Pemphigoid | - | - |
Empasiprubart IV | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
ARGX-119 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
ARGX-117 | Phase 2 | Multifocal Motor Neuropathy | - | - |
efgartigimod PH20 SC in stage B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
ARGX-119 IV | Phase 2 | Spinal Muscular Atrophy (SMA) | - | - |